Results 121 to 130 of about 138,424 (357)

Sequence analysis of sub-genotype D hepatitis B surface antigens isolated from Jeddah, Saudi Arabia. [PDF]

Saudi J Biol Sci, 2018
El Hadad S, Alakilli S, Rabah S, Sabir J.   +3 more
europepmc   +1 more source

Detection of e antigen and antibody: correlations with hapatitis B surface and hepatitis B core antigens, liver disease, and outcome in hepatitis B infections.

Gastroenterology, 1976
C. Trepo, L. Magnius, R. Schaefer, A. Prince   +3 more
semanticscholar   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, EarlyView.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source

Hepatitis B virus markers in hepatitis B surface antigen negative patients with pancreatic cancer: Two case reports

, 2022
Sergey Batskikh, Sergey Morozov, Dmitry Kostyushev   +2 more
openalex   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Positive hepatitis B surface antigen after vaccination in a newborn

, 2016
Mariana Leonel Martins, Ivete Afonso, Alexandrina Portela, Rui Almeida   +3 more
openalex   +1 more source

Nationwide Implementation of Double Reflex Testing for Hepatitis Delta in Spain: Results From the Retrospective Phase of the Spain‐DDR Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Nationwide implementation of double reflex testing for hepatitis delta in Spain markedly increased anti‐HDV and HDV viral load testing between 2022 and 2024, enabling national seroprevalence estimates. Despite this progress, substantial regional heterogeneity persists, highlighting the need for standardised reflex diagnostic protocols.
Ana Alberola, Adolfo de Salazar, Ana Fuentes, Raquel Carracedo, Marta Illescas‐López, María del Carmen Rodríguez Baños, Carolina Freyre, Berta Becerril, Isabel Viciana, Inmaculada López‐Rodríguez, Natalia Montiel, Ana María Domínguez Castaño, María Pilar Luzón‐García, Encarnación Ramírez Arellano, Carmen Liébana‐Martos, Francisco Franco Álvarez de Luna, María del Carmen Lozano, Begoña Palop, Antonio Sampedro, Ana Belén Pérez, Sonia Algarate, Susana Rojo Alba, Pablo Fraile, Dolores Ocete, María Jesús Alcaraz, Juan Carlos Rodríguez, Francisco Javier Hernández‐Felices, Olalla Martínez, Victoria Domínguez, Nieves Orta, Dolores Gómez, Carmen Cortell, Jorge Camacho, Susana Sabater, Luis Ángel Iglesias Sánchez, Yasmina Martín, Aldara Vallejo, Lourdes Molina, María Aroca, Beatriz Castro, Magdalena Lara, María José Pena, Ana Rodríguez‐Fernández, Alejandro González Praetorius, José Joaquín Blas, Alicia Beteta, César Gómez, María José Rodríguez, Soledad Illescas, Melanie Abreu, Julio García Díez, Inocencio Beltrán, Marta Sandoval Torrientes, Ruth Sáez, Teresa Martín, Pilar Tajada Alegre, Belén Lorenzo, María Teresa García Valero, Isabel Jiménez Sansegundo, Susana García‐de Cruz, Sonsoles Garcinuño, Miguel Ángel Sáiz, Santiago Muñoz, Isabel Fernández, Helena Miriam Lorenzo Juanes, María Reyes Vidal‐Acuña, Luz María Moldes, Noelia Calvo, Matilde Trigo, María José Gude, Patricia Ordóñez, Sandra Cortizo, Miriam Blasco, Mayra Sigcha, Iker Falces, Juan Carlos Galán, Ana Arribi, Roberto Alonso, Asunción Iborra, María Jesús del Amor Espín, Eva Cascales, Cayetano Pérez, Pablo Fernández, María Dolores Navarro, María Luz Nuñez, Jorge Galán Ros, Luis Javier Gil‐Gallardo, Ana Miqueleiz, Gabriel Reina, Luis Elorduy, Mikele Macho, Carmen Gómez, Paloma Liendo, Yolanda Salicio, Antonio Aguilera, Federico García   +95 more
wiley   +1 more source

Guidelines for Small-Scale Production and Purification of Hepatitis B Surface Antigen Virus-Like Particles from Recombinant Pichia pastoris

, 2019
Maria Zahid, Ursula Rinas
openalex   +2 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage.

Carcinogenesis, 2004
Yi‐Hsuan Hsieh, I. Su, Hui‐Ching Wang, Wen-Wei Chang, H. Lei, M. Lai, W. Chang, Wenya Huang   +7 more
semanticscholar   +1 more source